An underground market for unapproved weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.
Investigational Drug Gaining Popularity Via Social Media
The experimental drug, which remains in clinical trials, is being promoted by online personalities for its supposed weight-reducing effects. Viewers are encouraged to message these accounts directly for supplier links, while also obtaining discount codes.
Thriving Trade on Social Networks
Additionally, a robust market exists on Telegram, where groups with thousands of participants share “before and after” photos, injection guides and assertions of next-day British shipping. Vendors market the drug there before directing customers to WhatsApp for transactions.
Understanding Retatrutide
This medication is an experimental injection developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist patients reduce up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted online as the successor to Ozempic.
Healthcare Professionals Voice Concerns
However, physicians and chemists have cautions that the distribution of what remains an unlicensed drug in the UK is worrisome and could lead to individuals injecting substances of uncertain source.
Some professionals said the demand for retatrutide could be linked to the increasing cost of approved weight loss products such as Mounjaro.
Legal Status and Enforcement
Marketing retatrutide on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the British medical regulations.
Several content creators try to circumvent the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still violate pharmaceutical, marketing, and customer regulations, potentially leading to penalties, legal action or prison.
Platform Response and Content Removal
According to the social media company, the platform has taken down violative content and prohibited associated hashtags and query recommendations. The company said it was committed to keeping the platform secure and investing in strengthening enforcement strategies.
Digital Marketplace Activities
Investigations also discovered communities with up to nine thousand members selling retatrutide using the platform's built-in search feature, which functions like a online catalog. Typing “retatrutide” instantly displays groups with numerous of users, filled with photos of weight loss, glowing reviews and step-by-step instructions for mixing or injecting at home.
Within moments of joining one group, a vendor posted WhatsApp details, where the majority of transactions take place. The vendor provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one asked about body mass, medical conditions or past usage.
Product Information and Pricing
Within these groups, posts show dark colored packages with Royal Mail labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”
Buyers can select between powder vials, prepared at residence with purified liquid, or pre-filled injectors usually sold at 160 pounds for 20 milligrams. When questioned how much time a pen should be used, sellers give conflicting answers varying between a few weeks to “depends on your body”.
Service Oversight and Security Actions
A spokesperson for Telegram said it regularly monitored harmful content on its service including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“People are administering substances they cannot confirm. Although the research behind this drug is sound, these online products may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at Chemist4U.
Dr Crystal Wyllie of an online medical service linked the surge in demand to current price rises for authorized weight-loss medications such as Mounjaro. “With costs rising, individuals are using social media. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she explained.
Her team has previously encountered individuals harmed by personal administration from unverified suppliers. “We recognize the disappointment, but buying from Telegram or WhatsApp is taking chances with your health,” said the doctor. “These substances could be contaminated or incorrectly dosed.”
Manufacturer Statement
A representative from Eli Lilly said the substance was in phase 3 research studies and had not been reviewed or authorized by any government authority globally. “Therefore at this time no one can market [it] for human use,” they explained, adding that any product “falsely representing itself as a Lilly experimental substance not yet authorized … may subject patients to possibly serious health risks”.
